---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-055248"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:45:57.747162+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TELA Bio appoints Jeffrey Blizard as President; Blizard resigns from Board

## Summary
- Blizard resigned from Board effective June 2, 2025; no disagreement with company.
- Blizard appointed President effective same date; Antony Koblish remains CEO, drops President title.
- Annual base salary $475,000; target bonus 50% of salary; cash sign-on $150,000.
- Equity grant: 154,100 stock options (4-yr vest) and 104,800 RSUs (4-yr annual vest).
- Blizard previously Global Head of Surgical Sales at Abiomed (J&J); joined TELA Bio board June 2024.

## SEC filing metadata
- accession: 0001104659-25-055248
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/0001104659-25-055248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/tm2516546d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-055248
- JSON: https://secwatch.observer/filing/0001104659-25-055248.json
- Plain text: https://secwatch.observer/filing/0001104659-25-055248.txt

## Key facts
- Executive change
  Antony Koblish changed role as President at TELA Bio, Inc..
  - Action: relinquished
  - Role: President
  source text: Antony Koblish, the Company’s current President and Chief Executive Officer, will continue in his role as Chief Executive Officer, but as of the Effective Date will no longer hold the title of President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/0001104659-25-055248-index.htm
- Executive change
  Jeffrey Blizard resigned as Director at TELA Bio, Inc..
  - Action: resigned
  - Role: Director
  source text: Jeffrey Blizard, a member of the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”), tendered his resignation from the Board, effective as of June 2, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/0001104659-25-055248-index.htm
- Executive change
  Jeffrey Blizard was appointed as President at TELA Bio, Inc..
  - Action: appointed
  - Role: President
  source text: the Board appointed Jeffrey Blizard as the new President of the Company, effective as of June 2, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/0001104659-25-055248-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.